Lista de obras - Scott Metcalfe - Dominio Público Uruguay

A kick in the butt: time to address tobacco waste in New Zealand

artículo científico publicado en 2017

Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis

artículo científico publicado en 2013

Balancing the Risks and Benefits of Celecoxib

artículo científico publicado en 2007

Child abuse in Australian camps-whose business, and who should speak out?

artículo científico publicado en 2016

Climate science, denial and the Declaration of Delhi

artículo científico publicado en 2009

Combating antimicrobial resistance demands nation-wide action and global governance

artículo científico publicado en 2016

Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)

artículo científico publicado en 2014

Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold

artículo científico publicado en 2010

Direct-to-consumer advertising--yes it can compromise patient health

artículo científico publicado el 12 de septiembre de 2003

Dispensing patterns for antidiabetic agents in New Zealand: are the guidelines being followed?

artículo científico publicado en 2017

Do pharmaceutical score cards give us the answers we seek?

artículo científico publicado el 25 de noviembre de 2011

Fast, fair climate action crucial for health and equity

article

Funding a clinical trial: the perspective of a medicines funder

artículo científico publicado en 2008

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future

article

Global governance is a key part of the solution to antimicrobial resistance (response to Gravatt)

artículo científico publicado en 2016

Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis

artículo científico publicado en 2005

Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action

artículo científico publicado en 2014

Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand

artículo científico publicado en 2016

More about cardiovascular disease and lipid management in New Zealand

artículo científico publicado en 2002

More on PHARMAC and tobacco control in New Zealand

artículo científico publicado en 2006

National prescribing data for dabigatran

artículo científico publicado el 9 de marzo de 2012

New Zealand's emissions trading scheme and health: wasting our opportunities

artículo científico publicado en 2008

Old letters, new rules

scholarly article

Our advice? Get a budget!

scientific article published on 1 January 2002

Over and under? Ethnic inequities in community antibacterial prescribing

artículo científico publicado en 2019

PHARMAC and EpiPen for anaphylaxis

artículo científico publicado en 2006

PHARMAC and erythropoietin for cancer patients

artículo científico publicado en 2006

PHARMAC and statins--correction is needed

artículo científico publicado en 2007

PHARMAC and statins--getting the best population health gains

artículo científico publicado en 2006

PHARMAC and tobacco control in New Zealand: two licensed funded options are already available

artículo científico publicado en 2005

PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer

artículo científico publicado en 2007

PHARMAC has no cost-effectiveness threshold

artículo científico publicado el 24 de febrero de 2012

PHARMAC measures savings elsewhere to the health sector

artículo científico publicado en 2003

PHARMAC responds on Herceptin assumptions and decisions

artículo científico publicado en 2007

PHARMAC responds on TNF inhibitors for inflammatory arthritis

artículo científico publicado en 2005

PHARMAC responds on agents to prevent osteoporotic fractures

scientific article published on 10 March 2006

PHARMAC responds on long-acting inhalers for COPD

artículo científico publicado en 2005

PHARMAC responds on long-acting insulin analogues

scientific article published on 28 October 2005

PHARMAC responds on salbutamol

artículo científico publicado en 2005

PHARMAC responds on treatments for pulmonary arterial hypertension

artículo científico publicado en 2005

PHARMAC responds to Richard Milne on discounting health benefits and costs

scientific article published on 29 July 2005

PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists

artículo científico publicado en 2005

PHARMAC welcomes debate

scientific article published on 15 July 2005

PHARMAC's response on gemcitabine and transparency

artículo científico publicado en 2005

PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly

artículo científico publicado en 2005

PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate

artículo científico publicado en 2007

PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric

artículo científico publicado en 2012

Response from PHARMAC: difficult choices

artículo científico publicado en 2003

Response to Cameron et al "Mind the graph" Semin Oncol. 2018 [in press]

article

Response to letter to the editor on 'Mind the gap'

artículo científico publicado en 2017

Self-monitoring blood glucose test strip use with diabetes medicines in people with types 1 and 2 diabetes in New Zealand

artículo científico publicado en 2014

Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices

artículo científico publicado en 2004

Sign On - prescribing for climate health

artículo científico publicado en 2009

Specific oral contraceptive use and venous thromboembolism resulting in hospital admission

artículo científico publicado en 2004

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated

scholarly article

Te Wero tonu-the challenge continues: Māori access to medicines 2006/07-2012/13 update

scholarly article

Terminations of pregnancy associated with isotretinoin use in New Zealand

artículo científico publicado el 29 de julio de 2011

The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law now

artículo científico publicado en 2018

Time for healthy investment

artículo científico publicado en 2017

Trastuzumab: possible publication bias

scientific article published on 01 May 2008

Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity

artículo científico publicado el 25 de noviembre de 2011

Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis

artículo científico publicado en 2013

Why New Zealand must rapidly halve its greenhouse gas emissions

artículo científico publicado en 2009

Lista de obras de Scott Metcalfe

A kick in the butt: time to address tobacco waste in New Zealand

Assessing the value for money of pharmaceuticals in New Zealand--PHARMAC's approach to cost-utility analysis

Balancing the Risks and Benefits of Celecoxib

Child abuse in Australian camps-whose business, and who should speak out?

Climate science, denial and the Declaration of Delhi

Combating antimicrobial resistance demands nation-wide action and global governance

Comment on "ahead of its time? Reflecting on New Zealand's Pharmac following its 20th anniversary" : clarification from PHARMAC: PHARMAC takes no particular distributive approach (utilitarian or otherwise)

Comments on "Simoens, S. Health economic assessment: a methodological primer. Int. J. Environ. Res. Public Health 2009, 6, 2950-2966"-New Zealand in fact has no cost-effectiveness threshold

Direct-to-consumer advertising--yes it can compromise patient health

Dispensing patterns for antidiabetic agents in New Zealand: are the guidelines being followed?

Do pharmaceutical score cards give us the answers we seek?

Fast, fair climate action crucial for health and equity

Funding a clinical trial: the perspective of a medicines funder

Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future

Global governance is a key part of the solution to antimicrobial resistance (response to Gravatt)

Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis

Health and equity impacts of climate change in Aotearoa-New Zealand, and health gains from climate action

Mind the gap: An analysis of foregone health gains from unfunded cancer medicines in New Zealand

More about cardiovascular disease and lipid management in New Zealand

More on PHARMAC and tobacco control in New Zealand

National prescribing data for dabigatran

New Zealand's emissions trading scheme and health: wasting our opportunities

Old letters, new rules

Our advice? Get a budget!

Over and under? Ethnic inequities in community antibacterial prescribing

PHARMAC and EpiPen for anaphylaxis

PHARMAC and erythropoietin for cancer patients

PHARMAC and statins--correction is needed

PHARMAC and statins--getting the best population health gains

PHARMAC and tobacco control in New Zealand: two licensed funded options are already available

PHARMAC funding of 9-week concurrent trastuzumab (Herceptin) for HER2-positive early breast cancer

PHARMAC has no cost-effectiveness threshold

PHARMAC measures savings elsewhere to the health sector

PHARMAC responds on Herceptin assumptions and decisions

PHARMAC responds on TNF inhibitors for inflammatory arthritis

PHARMAC responds on agents to prevent osteoporotic fractures

PHARMAC responds on long-acting inhalers for COPD

PHARMAC responds on long-acting insulin analogues

PHARMAC responds on salbutamol

PHARMAC responds on treatments for pulmonary arterial hypertension

PHARMAC responds to Richard Milne on discounting health benefits and costs

PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists

PHARMAC welcomes debate

PHARMAC's response on gemcitabine and transparency

PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly

PHARMAC's updated guidelines for cost-effectiveness analyses, with new discount rate

PHARMAC's updated guidelines for cost-utility analyses, with new QALYs per $1M metric

Response from PHARMAC: difficult choices

Response to Cameron et al "Mind the graph" Semin Oncol. 2018 [in press]

Response to letter to the editor on 'Mind the gap'

Self-monitoring blood glucose test strip use with diabetes medicines in people with types 1 and 2 diabetes in New Zealand

Seretide meta-analysis missed important features and overstates any advantages over concurrent LABA/ICS devices

Sign On - prescribing for climate health

Specific oral contraceptive use and venous thromboembolism resulting in hospital admission

Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Celecoxib's relative gastrointestinal safety is overstated

Te Wero tonu-the challenge continues: Māori access to medicines 2006/07-2012/13 update

Terminations of pregnancy associated with isotretinoin use in New Zealand

The Zero Carbon Bill and the health of New Zealanders-help shape this crucial health law now

Time for healthy investment

Trastuzumab: possible publication bias

Usage and equity of access to isotretinoin in New Zealand by deprivation and ethnicity

Variation in the use of medicines by ethnicity during 2006/07 in New Zealand: a preliminary analysis

Why New Zealand must rapidly halve its greenhouse gas emissions